Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
83259 studies found for:    United States
Show Display Options
Rank Status Study
1 Recruiting Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Condition: Saphenous Vein Graft Atherosclerosis
Interventions: Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
2 Recruiting Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: PF-04965842;   Other: Placebo
3 Active, not recruiting PRC-063 in Adult ADHD
Condition: ADHD
Interventions: Drug: Placebo;   Drug: PRC-063 25 mg;   Drug: PRC-063 45 mg;   Drug: PRC-063 70 mg;   Drug: PRC-063 100 mg
4 Active, not recruiting A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100;   Biological: Placebo
5 Withdrawn Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Genetic: DNA analysis;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
6 Terminated A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
Conditions: Low Back Pain;   Low Back Pain, Recurrent
Interventions: Drug: JNJ-42160443 3 mg;   Drug: JNJ-42160443 1 mg;   Drug: JNJ-42160443 6 mg/3mg;   Drug: JNJ-42160443 10 mg;   Drug: Matching Placebo
7 Completed A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Interventions: Drug: PRT-201;   Drug: Placebo
8 Completed Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
Conditions: Brain Tumor;   Central Nervous System Tumor
Interventions: Drug: lomustine;   Drug: temozolomide
9 Active, not recruiting
Has Results
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: prednisone;   Drug: vincristine
10 Active, not recruiting Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Conditions: Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Drug: carboplatin;   Drug: thiotepa;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
11 Completed Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Drug: cyclosporine;   Drug: hydroxychloroquine;   Drug: prednisone;   Drug: tacrolimus
12 Completed Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: quetiapine fumarate tablets
13 Recruiting IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: IXAZOMIB + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
14 Terminated Contrast Media Reduction and Removal in Patients With CKD (PRESERV)
Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System;   Drug: Peri-procedural hydration
15 Completed A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Condition: Opioid-Induced Constipation (OIC)
Interventions: Drug: NKTR-118;   Drug: Placebo
16 Completed
Has Results
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release 50 mg;   Drug: Desvenlafaxine succinate sustained release 25 mg;   Drug: Placebo
17 Recruiting A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
Condition: Rosacea
Intervention: Drug: Azelaic acid
18 Completed
Has Results
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
Condition: Crohn's Disease
Intervention: Biological: Certolizumab Pegol (CDP870)
19 Terminated Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Condition: Cervical Cancer
Intervention: Drug: gemcitabine hydrochloride
20 Recruiting A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and/or 3;;   Squamous Lung Cancer With FGFR1 Amplification;;   Bladder Cancer With FGFR3 Mutation or Fusion
Intervention: Drug: BGJ398

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years